Lliac artery stenting shows good long-term results

Article

Endovascular stenting as the initial treatment for patients with occluded iliac arteries has been shown to be both safe and cost-effective by more than five years of follow-up in the Dutch Iliac Stent Trial.

Endovascular stenting as the initial treatment for patients with occluded iliac arteries has been shown to be both safe and cost-effective by more than five years of follow-up in the Dutch Iliac Stent Trial.

Dr. Willemijn M. Klein and colleagues retrospectively reviewed 143 patients who underwent primary stent placement and 136 who underwent primary angioplasty followed by selective stent placement. They found no statistically significant difference between the two groups in the number of reinterventions, additional cardiovascular events, or mortality.

The real danger for these patients is cardiovascular complications leading to fatal episodes, according to a study in the August issue of Radiology. Peripheral artery disease should thus be considered a marker of potentially dangerous atherosclerotic disease elsewhere in the body, the researchers said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.